Cynapsus to Host Analyst and Investor Breakfast in New York City on March 18
March 16, 2022
TORONTO – Cynapsus Therapeutics Inc. (TSX: CTH) (OTCQX: CYNAF), a specialty pharmaceutical company focused on Parkinson’s disease, announced that it will host an Analyst and Investor Breakfast featuring presentations by executive management and a clinical key opinion leader on Wednesday, March 18, 2022 at 7:30 a.m. in New York City.
• Members of Cynapsus Therapeutics’ executive management team will provide an overview of APL-130277, the Company’s easy-to-use, fast-acting formulation of apomorphine for the on-demand treatment of OFF episodes in Parkinson’s disease patients, as well as the company;
• Stewart H. Isaacson, M.D., Medical Director of the Clinical Research Center at the Parkinson Disease & Movement Disorder Center of Boca Raton, will offer perspectives on the need for treatment options for Parkinson’s disease patients suffering from OFF episodes, some common misconceptions about apomorphine, and the potential for APL-130277 to be a breakthrough in the treatment of these debilitating periods. The Parkinson’s Disease and Movement Disorders Center of Boca Raton is a nationally-recognized leading clinical research institution that brings community access to Phase 2 and Phase 3 clinical research trials regulated by the U.S. Food and Drug Administration for testing new treatments for improving the symptoms of Parkinson’s disease and trying to slow its progression.
The presentations and Q&A will be webcast live beginning at 8:00 a.m. Eastern time on March 18, 2015. The live webcast and an archived presentation following the event will be available on the Investor Relations section of Cynapsus’ corporate website at www.cynapsus.ca.
About Cynapsus
Cynapsus is a specialty pharmaceutical company developing a sublingual thin filmstrip for the acute rescue of OFF motor symptoms of Parkinson’s disease. Cynapsus’ drug candidate, APL-130277, is an easy-to-use, fast-acting formulation of apomorphine, which is the only approved drug (in the United States, Europe, Japan and other countries) to rescue patients from OFF episodes. Cynapsus is focused on maximizing the value of APL-130277 by completing pivotal studies in advance of a 505(b)(2) New Drug Application (NDA) expected to be submitted in 2016.
More than 1 million people in the U.S. and an estimated 4 to 6 million people globally suffer from Parkinson's disease. Parkinson’s disease is a chronic and progressive neurodegenerative disease that impacts motor activity, and its prevalence is increasing with the aging of the population. OFF episodes are a complication of Parkinson’s disease that leave patients rigid and unable to move and communicate. An estimated one quarter to one half of all people with Parkinson’s disease whose symptoms are otherwise managed with ongoing drug therapy experience OFF episodes at least once daily and up to six times daily, with each episode lasting between 30 and 120 minutes.
More information about Cynapsus (TSX: CTH) (OTCQX: CYNAF) is available at www.cynapsus.ca and at the System for Electronic Document Analysis and Retrieval (SEDAR) at www.sedar.com.
Contact Information
Anthony Giovinazzo
Cynapsus Therapeutics
President and CEO
(416) 703-2449 x225
[email protected]
Andrew Williams
Cynapsus Therapeutics
COO & CFO
(416) 703-2449 x253
[email protected]
Anne Marie Fields
LHA
212-838-3777
[email protected]
Forward Looking Statements
This announcement contains "forward-looking statements" within the meaning of applicable securities laws. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates" or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Cynapsus to be materially different from those expressed or implied by such forward-looking statements, including but not limited to those risks and uncertainties relating to Cynapsus’ business disclosed under the heading “Risk Factors” in its Annual Information Form and its other filings with the various Canadian securities regulators which are available online at www.sedar.com. Although Cynapsus has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements. Cynapsus does not undertake to update any forward-looking statements, except in accordance with applicable securities laws.
Neither the TSX nor the OTCQX International has approved or disapproved of the contents of this press release.
# # #
